Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor
Conditions
Interventions
Evolocumab
Placebo to Evolocumab
+2 more
Locations
58
United States
Research Site
Carmichael, California, United States
Research Site
Los Angeles, California, United States
Research Site
Mission Viejo, California, United States
Research Site
Thousand Oaks, California, United States
Research Site
Atlanta, Georgia, United States
Research Site
Atlanta, Georgia, United States
Start Date
January 24, 2013
Primary Completion Date
November 19, 2013
Completion Date
November 19, 2013
Last Updated
July 20, 2020
NCT06062394
NCT07230730
NCT07334834
NCT07311941
NCT06903897
NCT06055036
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions